AIMC Topic: Immunotherapy, Adoptive

Clear Filters Showing 11 to 15 of 15 articles

CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia.

Cancer letters
T cell acute lymphoblastic leukemia (T-ALL) is invasive and heterogeneous, and existing therapies are sometimes unsuccessful. Chimeric antigen receptor (CAR) T cell therapy is a breakthrough tumor treatment method, particularly for B cell acute lymph...

Machine learning-based cytokine microarray digital immunoassay analysis.

Biosensors & bioelectronics
Serial measurement of a large panel of protein biomarkers near the bedside could provide a promising pathway to transform the critical care of acutely ill patients. However, attaining the combination of high sensitivity and multiplexity with a short ...

Advancing T-cell immunotherapy for cellular senescence and disease: Mechanisms, challenges, and clinical prospects.

Ageing research reviews
Cellular senescence is a complex biological process with a dual role in tissue homeostasis and aging-related pathologies. Accumulation of senescent cells promotes chronic inflammation, tissue dysfunction, age-related diseases, and tumor suppression. ...

Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges.

Blood cancer discovery
Artificial intelligence could enhance chimeric antigen receptor T-cell therapy outcomes through optimization of all steps, from target identification, vector design, and manufacturing to personalized data-driven clinical decisions. In this report, we...

New tools for MHC research from machine learning and predictive algorithms to the tumour immunopeptidome.

Immunology
At a time when immunology seeks to progress ever more rapidly from characterization of a microbial or tumour antigen to the immune correlates that may define protective T-cell immunity, there is a need for robust tools to enable accurate predictions ...